The agreement establishes BioHorizons as the exclusive distributor of Xtant's allogeneic growth factor technology into the dental and oral-maxillofacial procedure markets in the United States and Canada, expanding access to the advanced allograft technology for clinicians served by the BioHorizons commercial organization. The partnership reflects a long-term strategic relationship between the two companies, combining Xtant's regenerative medicine development and manufacturing capabilities with BioHorizons' established commercial reach and customer relationships. Both companies expect the collaboration to create a durable channel for expanding access to Prolifica™ and to serve as a foundation for continued collaboration between the organizations.

Sean Browne, President and CEO of Xtant Medical, stated, "This exclusive partnership brings together Xtant's expertise in regenerative biologics with BioHorizons' trusted commercial organization, positioning both companies to deliver meaningful value to clinicians and the patients they serve. We look forward to a productive, long-standing collaboration."

Steve Boggan, President and CEO of BioHorizons, stated, "Prolifica™ is a strong complement to our regenerative portfolio, and this partnership allows us to bring advanced allogeneic growth factors to more of the clinicians who rely on us. We look forward to a long-term collaboration that benefits both organizations and, most importantly, the patients we collectively serve."

Prolifica™ is a naturally occurring blend of allogeneic growth factors, stabilized by native human collagen and delivered in their intrinsic structure, concentration, and composition. Processed to preserve the natural biphasic release of proteins, this advanced allograft supports bone healing and regeneration across a range of clinical applications.

Prolifica™ is now accessible to clinicians through BioHorizons' commercial network.